Avenue therapeutics enters into a transformational license agreement with annji pharmaceutical to develop and commercialize aj201, a first-in-class clinical asset for the treatment of spinal and bulbar muscular atrophy

Aj201 is being evaluated in a phase 1b/2a clinical trial in the u.s. for the rare x-linked genetic neurodegenerative disease also known as kennedy's disease which currently has no fda approved therapy aj201 is being evaluated in a phase 1b/2a clinical trial in the u.s. for the rare x-linked genetic neurodegenerative disease also known as kennedy's disease which currently has no fda approved therapy
ATXI Ratings Summary
ATXI Quant Ranking